| |
| Trade Name | CONTAK RENEWAL 3 AVT CRT-D SYSTEM |
| Classification Name | defibrillator, automatic implantable cardioverter, with cardiac resynchronization (crt-d) |
| Generic Name | device resynchronization therapy-defibrillator (crt-d) system |
| Applicant | GUIDANT CORP. |
| PMA Number | P010012 |
| Supplement Number | S037 |
| Date Received | 11/10/2004 |
| Decision Date | 03/13/2008 |
| Product Code | |
| Docket Number | 08M-0243 |
| Notice Date | 04/24/2008 |
| Advisory Committee |
Cardiovascular |
| Supplement Type | panel track |
| Supplement Reason | change design/components/specifications - specifications |
| Expedited Review Granted? | No |
| Combination Product |
No
|
| Information About: |
Labeling, Approval Order, Summary of Safety and Effectiveness |
Approval Order Statement Approval for the contak renewal 3 avt and contak renewal 3 avt he systems. The systems are indicated for the following: contak renewal 3 avt cardiac resynchronization therapy defibrillators (crt-ds) are indicated for patients with moderate to severe heart failure (nyha iii/iv) who remain symptomatic despite stable, optimal heart failure drug therapy, and have left ventricular dysfunction (ef <= 35%) and qrs duration >= 120 ms. Contak renewal 3 avt provides atrial antitachycardia pacing and atrial defibrillation treatment for patients with a history of or who are at risk of developing atrial arrhythmias. |
| Approval Order |
Approval Order
|